Cargando…
Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections
Relebactam is a small‐molecule β‐lactamase inhibitor developed as a fixed‐dose combination with imipenem/cilastatin. The pharmacokinetics of relebactam and imipenem across 10 clinical studies were analyzed using data from adult healthy volunteers and patients with bacterial infections. Renal functio...
Autores principales: | Bhagunde, Pratik, Patel, Parul, Lala, Mallika, Watson, Kenny, Copalu, William, Xu, Ming, Kulkarni, Pooja, Young, Katherine, Rizk, Matthew L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813166/ https://www.ncbi.nlm.nih.gov/pubmed/31508899 http://dx.doi.org/10.1002/psp4.12462 |
Ejemplares similares
-
Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia
por: Patel, Munjal, et al.
Publicado: (2021) -
Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants
por: Rhee, Elizabeth G., et al.
Publicado: (2018) -
Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects
por: Rizk, Matthew L., et al.
Publicado: (2018) -
Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections
por: Heo, Young-A.
Publicado: (2021) -
Genomic Characterization of Imipenem- and Imipenem-Relebactam-Resistant Clinical Isolates of Pseudomonas aeruginosa
por: López-Pérez, Mario, et al.
Publicado: (2021)